Darryl Maher

Mr Maher adds global biopharmaceutical and commercialization capability to the Cynata board, with over 23 years of experience with CSL Limited. CSL is one of the world's most successful developers of biologic pharmaceutical products and has a market capitalization of ~A$130 billion. Dr Maher has had a long career in pharmaceutical product development, most recently as the former Vice President of R&D and Medical Affairs at CSL Behring Australia where he was responsible for the development of multiple successful drug products from initiation through to clinical development and ultimately to commercialization. Dr Maher undertook medical training, qualified as a specialist hematologist.